ENUMERAL BIOMEDICAL HOLDINGS, INC. (ENUM) financial statements (2020 and earlier)

Company profile

Business Address 200 CAMBRIDGEPARK DRIVE, SUITE 2000
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
10/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,1623,59613,47018
Cash and cash equivalents3,1623,59610,46018
Short-term investments  3,010 
Receivables189306284 
Other current assets   6
Other undisclosed current assets47280202 
Total current assets:3,3994,18313,95724
Noncurrent Assets
Property, plant and equipment9021,5111,007 
Restricted cash and investments535535562 
Other noncurrent assets1121158 
Total noncurrent assets:1,5482,1611,578 
TOTAL ASSETS:4,9476,34415,53524
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3093446142
Accounts payable3093446142
Debt252240  
Derivative instruments and hedges, liabilities 2,13816,119 
Due to related parties  78 
Deferred revenue and credits15131236 
Other undisclosed current liabilities38671471 
Total current liabilities:9613,56717,1172
Noncurrent Liabilities
Long-term debt and lease obligation15266  
Capital lease obligations15266  
Liabilities, other than long-term debt633710113
Deferred revenue and credits6337101 
Due to related parties   13
Total noncurrent liabilities:7830310113
Total liabilities:1,0393,87117,21915
Stockholders' equity
Stockholders' equity attributable to parent3,9082,473(1,684)9
Common stock12852526
Additional paid in capital30,04516,82215,96523
Accumulated other comprehensive loss  (10) 
Accumulated deficit(26,265)(14,401)(17,691)(20)
Total stockholders' equity:3,9082,473(1,684)9
TOTAL LIABILITIES AND EQUITY:4,9476,34415,53524

Income statement (P&L) ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
10/31/2013
Gross profit:2,4531,489164 
Operating expenses(9,426)(12,190)(6,595)(19)
Operating loss:(6,973)(10,700)(6,431)(19)
Nonoperating income (expense)(4,883)13,990(1,749) 
Other nonoperating expense  (1,691) 
Interest and debt expense(4,266)10(242) 
Income (loss) from continuing operations before equity method investments, income taxes:(16,122)3,300(8,422)(19)
Other undisclosed income (loss) from continuing operations before income taxes4,266(10)242 
Net income (loss) available to common stockholders, diluted:(11,856)3,290(8,179)(19)

Comprehensive Income ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
10/31/2013
Net income (loss):(11,856)3,290(8,179)(19)
Other comprehensive loss (3,300)  
Comprehensive loss:(11,856)(10)(8,179)(19)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (10) 
Comprehensive loss, net of tax, attributable to parent:(11,856)(10)(8,189)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: